tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Cleo Diagnostics Reports Increased Losses and Revenue Decline for 2025

Story Highlights
Cleo Diagnostics Reports Increased Losses and Revenue Decline for 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

CLEO Diagnostics Ltd ( (AU:COV) ) just unveiled an announcement.

Cleo Diagnostics Limited reported a 12.8% decrease in revenues to $339,590 for the year ending June 30, 2025, alongside a 6.4% increase in losses, totaling $3,999,134. The company did not declare any dividends for the period, and the net tangible assets per ordinary security decreased from 6.99 cents to 4.26 cents, indicating financial challenges and potential implications for stakeholders.

More about CLEO Diagnostics Ltd

Cleo Diagnostics Limited operates in the healthcare industry, focusing on diagnostic services and products. The company is involved in developing and providing diagnostic solutions, although specific market focus details are not provided.

Average Trading Volume: 68,152

Technical Sentiment Signal: Hold

Find detailed analytics on COV stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1